Studies have shown that TP53 and FLT3 mutations are common resistance-related mutations in AML patients (18), and GO treatment may lead to the selection and expansion of these resistant clones, thereby increasing the probability of t-AML occurrence. Here, TP53 is linked to acute myeloid leukemia.